

PharmLabs San Diego Certificate of Analysis



Sample Puffs - Purple Haze

Delta9 THC UI	THCa 0.27%	Total THC (THCa * 0.877 + THC) 0.24%	Delta8 THC 51.49%
---------------	------------	--------------------------------------	-------------------

Sample ID SD241123-030 (101244)	Matrix Concentrate
Tested for Cali Extrax	
Sampled -	Received Nov 22, 2024
Analyses executed CANX	Reported Nov 27, 2024

Laboratory note: The Δ9-THC results in this particular sample is inconclusive due to potential interferences from several cannabinoids when analyzed using our GC MS/MS D9C method. As a result, this sample will not undergo testing via the GC MS/MS D9C method. However, there are currently no interferences detected with any other cannabinoids in this sample when employing HPLC.

CANx - Cannabinoids Analysis

Analyzed Nov 27, 2024 | Instrument HPLC-VWD | Method SOP-001  
 The expanded Uncertainty of the Cannabinoid analysis is approximately ±.806% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND
Cannabidiol (CBDO)	0.002	0.007	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.01	0.031	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.007	0.021	ND	ND
Cannabidiolic Acid (CBDA)	0.001	0.16	1.30	12.96
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND
Cannabigerol (CBG)	0.001	0.16	ND	ND
Cannabidiol (CBD)	0.001	0.16	8.03	80.33
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.013	0.041	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.025	0.075	ND	ND
Tetrahydrocannabinol (THCV)	0.001	0.16	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.021	0.064	0.65	6.53
Cannabidiol (CBDH)	0.005	0.16	ND	ND
Tetrahydrocannabinol (Δ9-THCB)	0.013	0.038	0.16	1.60
Cannabinol (CBN)	0.001	0.16	3.27	32.67
Cannabidiophorol (CBDP)	0.015	0.047	ND	ND
exo-THC (exo-THC)	0.005	0.16	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	51.49	514.87
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.126	0.42	ND	ND
Hexahydrocannabinol (S isomer) (9s-HHC)	0.017	0.16	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.118	0.39	ND	ND
Hexahydrocannabinol (R isomer) (9r-HHC)	0.016	0.16	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	0.27	2.69
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.024	0.071	ND	ND
Cannabinol Acetate (CBNO)	0.014	0.043	0.49	4.93
Δ9-Tetrahydrocannabinol (Δ9-THCP)	0.017	0.16	4.91	49.11
Δ8-Tetrahydrocannabinol (Δ8-THCP)	0.041	0.16	ND	ND
Cannabicitran (CBT)	0.005	0.16	0.63	6.33
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	ND	ND
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	ND	ND
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.008	0.025	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	ND	ND
<b>Total THC ( THCa * 0.877 + Δ9THC )</b>			<b>0.24</b>	<b>2.36</b>
<b>Total THC + Δ8THC + Δ10THC ( THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC )</b>			<b>51.72</b>	<b>517.23</b>
<b>Total CBD ( CBDA * 0.877 + CBD )</b>			<b>9.17</b>	<b>91.70</b>
<b>Total CBG ( CBGA * 0.877 + CBG )</b>			<b>ND</b>	<b>ND</b>
<b>Total HHC ( 9r-HHC + 9s-HHC )</b>			<b>ND</b>	<b>ND</b>
<b>Total Cannabinoids Analyzed</b>			<b>71.01</b>	<b>710.10</b>

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC  
 DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Wed, 27 Nov 2024 10:42:26 -0800

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



\*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.